Sojourn Inhalant

Sojourn Inhalant Uses, Dosage, Side Effects, Food Interaction and all others data.

Sojourn Inhalant is a volatile halogenated general anaesthetic that has a minimum alveolar concentration (MAC) value ranging from 1.4% to 3.3%. It alters the activity of fast synaptic neurotransmitter receptors like nicotinic acetylcholine, GABA, and glutamate. It may depress myocardial contractility and decrease both BP and sympathetic nervous activity. Additionally, it has muscle relaxant properties w/o analgesia.

Sojourn Inhalant induces muscle relaxation and reduces pains sensitivity by altering tissue excitability with a fast onset of action. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.

Trade Name Sojourn Inhalant
Availability Prescription only
Generic Sevoflurane
Sevoflurane Other Names Sevofluran, Sevoflurane, Sevoflurano, Sevofluranum
Related Drugs fentanyl, lidocaine, ketamine, hyoscyamine, propofol, glycopyrrolate
Type Inhalation anesthetic
Formula C4H3F7O
Weight Average: 200.0548
Monoisotopic: 200.007212153
Groups Approved, Vet approved
Therapeutic Class General (Inhalation) anesthetics
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Sojourn Inhalant
Sojourn Inhalant

Uses

Sojourn Inhalant is used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sojourn Inhalant should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitationmust be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used.

Sojourn Inhalant is also used to associated treatment for these conditions: General Anesthesia, Induction and Maintenance of General Anesthesia

How Sojourn Inhalant works

Sojourn Inhalant induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sojourn Inhalant also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor, and the glycine receptor.

Dosage

Sojourn Inhalant dosage

he concentration of sevoflurane being delivered from a vaporizer during anesthesia should be known. This may be accomplished by using a vaporizer calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient's response.

Replacement Of Desiccated CO2Absorbents: When a clinician suspects that the CO2absorbent may be desiccated, it should be replaced. The exothermic reaction that occurs with sevoflurane and CO2absorbents is increased when the CO2absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO2absorbent canisters

Pre-anesthetic Medication: No specific premedication is either indicated or contraindicated with sevoflurane. The decision as to whether or not to premedicate and the choice of premedication is left to the discretion of theanesthesiologist

Induction: Sojourn Inhalant has a nonpungent odor and does not cause respiratory irritability; it is suitable for mask induction inpediatricsand adults

Maintenance: Surgical levels of anesthesia can usually be achieved with concentrations of 0.5-3% sevoflurane with or without the concomitant use ofnitrous oxide. Sojourn Inhalant can be administered with any type of anesthesia circuit

Side Effects

Cardiorespiratory depression, hypotension, bradycardia; laryngospasm, increased cough and salivation; urinary retention, acute renal failure, changes in liver enzyme values, liver damage; nausea, vomiting, delirium, seizure; rash, urticaria, pruritus, dyspnoea, wheezing, chest discomfort, bronchospasm, anaphylactic/anaphylactoid reaction; agitation, dystonic movements (childn).

Toxicity

LC50=49881 ppm/hr (rat), LD50=10.8 g/kg (rat)

Precaution

Patient with increased intracranial pressure, neuromuscular disease (esp Duchenne muscular dystrophy), mitochondrial disorders. Patient who are hypovolaemic, hypotensive, haemodynamically compromised, at risk of QT prolongation. Hepatic and renal impairment. Childn. Pregnancy and lactation.

Interaction

Increased metabolism and toxicity with drugs that induce CYP2E1 isoenzyme (e.g. isoniazid). Reduced MAC with benzodiazepines, opioids. May cause ventricular arrhythmia with β-sympathomimetic agents (e.g. isoprenaline), and α- and β-sympathomimetic agents (e.g. adrenaline, noradrenaline). May cause crisis during operation with nonselective MAO inhibitors. May lead to marked hypotension and risk of additive negative inotropic effect with Ca antagonists (esp dihydropyridines).

Food Interaction

No interactions found.

Elimination Route

Rapidly absorbed into circulation via the lungs, however solubility in the blood is low.

Half Life

15-23 hours

Elimination Route

The low solubility of sevoflurane facilitates rapid elimination via the lungs. In vivo metabolism studies suggest that approximately 5% of the sevoflurane dose may be metabolized. Up to 3.5% of the sevoflurane dose appears in the urine as inorganic fluoride.

Pregnancy & Breastfeeding use

Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 1 MAC (minimum alveolar concentration) without CO2 absorbent and have revealed no evidence of impaired fertility or harm to the fetus due to sevoflurane at 0.3 MAC, the highest nontoxic dose. Developmental and reproductive toxicity studies of sevoflurane in animals in the presence of strong alkalies (i.e., degradation of sevoflurane and production of Compound A) have not been conducted. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, sevoflurane should be used during pregnancy only if clearly needed.

Labor And Delivery: Sojourn Inhalant has been used as part of general anesthesia for elective cesarean section in 29 women. There were no untoward effects in mother or neonate (see Pharmacodynamics - Clinical Trials). The safety of sevoflurane in labor and delivery has not been demonstrated.

Nursing Mothers: The concentrations of sevoflurane in milk are probably of no clinical importance 24 hours after anesthesia. Because of rapid washout, sevoflurane concentrations in milk are predicted to be below those found with many other volatile anesthetics.

Contraindication

Sojourn Inhalant can cause malignant hyperthermia. It should not be used in patients with known sensitivity to sevoflurane or to other halogenated agents nor in patients with known or suspected susceptibility to malignant hyperthermia.

Special Warning

Geriatric Use: MAC decreases with increasing age. The average concentration of sevoflurane to achieve MAC in an 80 year old is approximately 50% of that required in a 20 year old.

Pediatric Use: Induction and maintenance of general anesthesia with sevoflurane have been established in controlled clinical trials in pediatric patients aged 1 to 18 years. Sojourn Inhalant has a nonpungent odor and is suitable for mask induction in pediatric patients.

The concentration of sevoflurane required for maintenance of general anesthesia is age dependent. When used in combination with nitrous oxide, the MAC equivalent dose of sevoflurane should be reduced in pediatric patients. MAC in premature infants has not been determined.

The use of sevoflurane has been associated with seizures. The majority of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgement should be exercised when using sevoflurane in patients who may be at risk for seizures.

Acute Overdose

In the event of overdosage, or what may appear to be overdosage, the following action should be taken: discontinue administration of sevoflurane, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function.

Storage Condition

Store between 15-30° C. Protect from light.

Innovators Monograph

You find simplified version here Sojourn Inhalant

Sojourn Inhalant contains Sevoflurane see full prescribing information from innovator Sojourn Inhalant Monograph, Sojourn Inhalant MSDS, Sojourn Inhalant FDA label

FAQ

What is Sojourn Inhalant used for?

Sojourn Inhalant used to treat induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery.

How safe is Sojourn Inhalant?

it has no effect on the normal cardiac conduction pathways and therefore is considered a safe agent that can also be used in cardiac electrophysiological procedures.

How does Sojourn Inhalant work?

These work by temporarily reducing the activity of the body's central nervous system.

What are the common side effects of Sojourn Inhalant?

The most common side effects of Sojourn Inhalant are include: nausea, vomiting, hypotension, agitation, and cough.

Is Sojourn Inhalant safe during pregnancy?

Sojourn Inhalant should be used during pregnancy only if clearly needed.

Is Sojourn Inhalant safe during breastfeeding?

Advise women to skip breastfeeding for 48 hours after administration and discard milk produced during this period.

Can I drink alcohol with Sojourn Inhalant?

drink alcohol containing drinks on a regular basis may require higher doses of Sojourn Inhalant and are at increased risk of developing severe liver side effects. Limit or avoid Alcoholic beverages before and after surgery.

Can I drive after taking Sojourn Inhalant?

It may also cause problems with coordination and ability to think. Therefore, for about 24 hours (or longer if necessary) after receiving Sojourn Inhalant, do not drive, operate moving machinery, or do anything else that could be dangerous if you are not alert .

How long does it take for Sojourn Inhalant to work?

Sojourn Inhalant usually produce surgical anaesthesia in less than 2 minutes.

How long does Sojourn Inhalant stay in my system?

The duration of anesthesia was not different between groups and averaged 114.3 min and 119.0 min for Sojourn Inhalant and isoflurane, respectively.

Is Sojourn Inhalant a muscle relaxant?

Sojourn Inhalant increased sensitivity to muscle relaxants but no direct muscle relaxation.

How do I give Sojourn Inhalant?

Sojourn Inhalant is administered via inhalation of the vaporised liquid. 

Does Sojourn Inhalant increase blood pressure?

Sojourn Inhalant progressively decrease blood pressure and this decrease appears similar to isoflurane and desflurane.

Does Sojourn Inhalant cause tachycardia?

Sojourn Inhalant was not associated with increases in heart rate in adult patients and volunteers, whereas higher MACs of isoflurane and desflurane and rapid increases in the inspired concentrations of these two anesthetics have been associated with tachycardia.

Does Sojourn Inhalant cause hypotension?

Sojourn Inhalant did not alter heart rate, but decreased mean arterial pressure and mean pulmonary artery pressure.

Can I take overdose of Sojourn Inhalant?

In the event of Sojourn Inhalant, or what may appear to be overdosage, the following action should be taken: discontinue administration of Sojourn Inhalant, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function.

What happen If I missed Sojourn Inhalant?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

*** Taking medicines without doctor's advice can cause long-term problems.
Share